Queen's University Belfast spin-out developing sustained-release ocular drug delivery technology.
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Series A Belfast-based Re-Vana Therapeutics raised an oversubscribed $11.9m Series A led by Visionary Ventures to advance its ocular drug delivery technology. | $11.9M |